Collaborations

Picture4We are involved in a number of research collaborations with major pharmaceutical companies.  These range from early stage research establishing target tractability through to late lead optimisation programs. We value close co-operation with our collaborators to ensure the combined strengths of the partners are most effectively deployed to deliver drug candidates.

Current disclosed collaborations include

  • Servier, two development stage collaborations on Bcl-2 family of proteins and two further research collaborations on undisclosed oncology targets
  • Lundbeck, a research collaboration targetting LRRK2
  • Asahi Kasei Pharmaceuticals, a research collaboration targetting Rheumatoid Arthritis
  • Taisho Pharmaceuticals Co., Ltd, a research collaboration targetting an undisclosed target

 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...

 

NCE Pipeline

NCE-thumbnailExplore the pipeline ...

 

Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1